Dysautonomia (Autonomic Dysfunction) Market Trends Analysis By DelveInsight
Autonomic Dysfunction develops when the nerves of the ANS are damaged. This condition is called Autonomic Neuropathy or Dysautonomia. Autonomic dysfunction can range from mild to life-threatening. It can affect a part of the ANS or the entire ANS. Sometimes the conditions that cause problems are temporary and reversible. Others are chronic, or long-term, and may continue to worsen over time. Diabetes and Parkinson’s disease are two examples of chronic conditions that can lead to autonomic dysfunction.
Autonomic dysfunction can affect a small part of the ANS (Autonomic Nervous System) or the entire ANS. Some symptoms that may indicate the presence of an autonomic nerve disorder include dizziness and fainting upon standing up, or orthostatic hypotension, exercise intolerance, sweating abnormalities, digestive difficulties, such as a loss of appetite, bloating, diarrhoea, constipation, or difficulty swallowing.
As per the study conducted by José Javier Mendoza-Velásquez et al. 2019, Parkinson's disease (PD) is the second-most-common neurodegenerative disease, affecting two to three percent of the population above 65 years of age. The prevalence of autonomic dysfunction in PD ranges between 50% and 70%. The most common dysautonomic symptoms in PD are constipation, urinary dysfunction, and orthostatic hypotension (OH).
DelveInsight's "Dysautonomia (Autonomic Dysfunction) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Dysautonomia (Autonomic Dysfunction) Market, historical and forecasted epidemiology, the pipeline insight as well as the Dysautonomia (Autonomic Dysfunction) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Dysautonomia (Autonomic Dysfunction) Market Trends
In the coming years, the expected launch of the emerging therapies shall fuel the Dysautonomia (Autonomic Dysfunction) market growth. The other factors that shall further expedite the market growth include increasing morbidity rate of Autonomic dysfunction and increasing awareness about available treatments. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Autonomic dysfunction.
The Dysautonomia (Autonomic Dysfunction) market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Dysautonomia (Autonomic Dysfunction) market trends and growth by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Dysautonomia (Autonomic Dysfunction) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Dysautonomia (Autonomic Dysfunction) Epidemiology Forecast
The Dysautonomia (Autonomic Dysfunction) epidemiology section covers insights about historical and current Dysautonomia (Autonomic Dysfunction) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognise the causes of current and forecasted Dysautonomia (Autonomic Dysfunction) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Dysautonomia (Autonomic Dysfunction) Companies operating in the market include Celltex Therapeutics, Theravance Biopharma, PTC Therapeutics, and many others.
Dysautonomia (Autonomic Dysfunction) Therapies Covered in the report include Mesenchymal stem cells, TD-9855, PTC258, and many more.
For more details, visit: Dysautonomia (Autonomic Dysfunction) Market Trends